JPH03504597A - インスリン様成長因子活性の強化および阻害方法 - Google Patents

インスリン様成長因子活性の強化および阻害方法

Info

Publication number
JPH03504597A
JPH03504597A JP63505194A JP50519488A JPH03504597A JP H03504597 A JPH03504597 A JP H03504597A JP 63505194 A JP63505194 A JP 63505194A JP 50519488 A JP50519488 A JP 50519488A JP H03504597 A JPH03504597 A JP H03504597A
Authority
JP
Japan
Prior art keywords
igf
protein
binding protein
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63505194A
Other languages
English (en)
Japanese (ja)
Inventor
クレモンズ，デイヴィッド，アール．
バスビー，ウォーカー，エッチ．ジュニア
ブリュアー，マイケル，ティー．
エイゼンバーグ，ステファン，ピー．
トンプソン，ロバート，シー．
Original Assignee
シナージェン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シナージェン，インコーポレーテッド filed Critical シナージェン，インコーポレーテッド
Publication of JPH03504597A publication Critical patent/JPH03504597A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymerisation Methods In General (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
JP63505194A 1988-04-12 1988-06-03 インスリン様成長因子活性の強化および阻害方法 Pending JPH03504597A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18075988A 1988-04-12 1988-04-12

Publications (1)

Publication Number Publication Date
JPH03504597A true JPH03504597A (ja) 1991-10-09

Family

ID=22661666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63505194A Pending JPH03504597A (ja) 1988-04-12 1988-06-03 インスリン様成長因子活性の強化および阻害方法

Country Status (7)

Country Link
EP (1) EP0418230B1 (fr)
JP (1) JPH03504597A (fr)
AT (1) ATE132164T1 (fr)
AU (1) AU1955388A (fr)
BR (1) BR8901711A (fr)
DE (1) DE3854842T2 (fr)
WO (1) WO1989009792A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE125268T1 (de) * 1988-07-15 1995-08-15 Cent Sydney Area Health Serv Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein- komplexes.
US6465423B1 (en) 1988-07-15 2002-10-15 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
US5324820A (en) * 1988-07-15 1994-06-28 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
JPH06503711A (ja) * 1990-08-28 1994-04-28 カイロン　コーポレイション 新規インシュリン様成長因子結合タンパク質（ｉｇｆｂｐ―４）
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
DE69233155T2 (de) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
DE69333063T2 (de) 1992-11-04 2004-05-13 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Vekürztes insulinähnlichen wachstumsfaktor-bindendes protein mit mitogener aktivität
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
CA2160154A1 (fr) * 1993-04-07 1994-10-13 George N. Cox Methodes d'utilisation de proteines de fixation de facteur de croissance de type insuline
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
DK1141015T3 (da) 1999-01-06 2010-01-25 Genentech Inc Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
EP1282437B1 (fr) 2000-05-16 2008-03-19 Genentech, Inc. Traitement des lesions du cartilage
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
CA2538342C (fr) 2003-09-12 2013-01-08 Tercica, Inc. Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (igf-1)
EP1670822A2 (fr) 2003-10-03 2006-06-21 Genentech, Inc. Proteines de liaison a l'igf
JP2020533344A (ja) 2017-09-11 2020-11-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 慢性肺疾患を治療するための方法および組成物
CA3194764A1 (fr) 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions appropriees pour une utilisation chez des nouveau-nes
WO2023139115A1 (fr) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions et procédés pour réduire l'oxydation d'igf‐1/igfbp
WO2023242439A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Stabilisation vasculaire (nourrissons prématurés)
WO2023242440A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Traitement des poumons chez les nourrissons
WO2023242442A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Procédé de maturation/différenciation de neurones et/ou de modulation du nerf vague

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502986A (ja) * 1987-04-06 1989-10-12 セルトリックス　ファーマシュウティカルズ，インク 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
JPH03504494A (ja) * 1988-03-11 1991-10-03 エラスムス、ユニベルシテイト Ｉｇｆ結合タンパク質、ｉｇｆ結合タンパク質をコードするｄｎａ構造体及びこのｄｎａ構造体を含有したベクター

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CA1209501A (fr) * 1982-09-16 1986-08-12 Nikos Panayotatos Vecteur d'expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502986A (ja) * 1987-04-06 1989-10-12 セルトリックス　ファーマシュウティカルズ，インク 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
JPH03504494A (ja) * 1988-03-11 1991-10-03 エラスムス、ユニベルシテイト Ｉｇｆ結合タンパク質、ｉｇｆ結合タンパク質をコードするｄｎａ構造体及びこのｄｎａ構造体を含有したベクター

Also Published As

Publication number Publication date
EP0418230A1 (fr) 1991-03-27
BR8901711A (pt) 1989-11-21
DE3854842T2 (de) 1996-06-13
EP0418230B1 (fr) 1995-12-27
ATE132164T1 (de) 1996-01-15
WO1989009792A1 (fr) 1989-10-19
AU1955388A (en) 1989-11-03
DE3854842D1 (de) 1996-02-08
EP0418230A4 (en) 1991-10-23

Similar Documents

Publication Publication Date Title
JPH03504597A (ja) インスリン様成長因子活性の強化および阻害方法
Steiner et al. Isolation and properties of proinsulin, intermediate forms, and other minor components from crystalline bovine insulin
King et al. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor
KR100230156B1 (ko) 종양괴사인자 억제제 및 그 제조방법
EP0055945A2 (fr) Proinsuline humaine, ses analogues, méthode de préparation par expression polypeptidique microbienne et sa conversion en insuline humaine
KR0148009B1 (ko) 인터루킨-1 억제제
Forssmann et al. The auricular myocardiocytes of the heart constitute an endocrine organ characterization of a porcine cardiac peptide hormone, cardiodilatin-126
JP3207416B2 (ja) ソマトトロピン・アナログ類
CZ171492A3 (en) Polypeptide, process of its preparation, pharmaceutical composition containing thereof and its use as an intermediate for insulin preparation
KR970002917B1 (ko) 인터루킨-i 억제제
WO2013039996A1 (fr) Compositions et procédés pour induction et activité de tissu adipeux brun à l'aide de fndc5
WO2014116556A2 (fr) Compositions et procédés pour la régulation de la thermogenèse et de l'inflammation musculaire à l'aide de metrnl et metrn
McKay et al. The complete primary structure of pancreatic polypeptide from the European common frog, Rana temporaria
Boismenu et al. Purification and characterization of human and mouse recombinant alpha-fetoproteins expressed inEscherichia coli
EP0422049A4 (en) Vector for secretion of proteins directly into periplasm or culture medium
US5605815A (en) Nucleic acids encoding and expression of parathyroid hormone-like peptide
Thorne et al. Expression of mouse proopiomelanocortin in an insulinoma cell line: requirements for β-endorphin processing
JPH03503596A (ja) 蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用
Upton et al. Evolution of insulin-like growth factor (IGF) function: production and characterization of recombinant hagfish IGF
Upton et al. Production and characterization of recombinant chicken insulin-like growth factor-II from Escherichia coli
Upton et al. Production and characterization of recombinant chicken insulin-like growth factor-I from Escherichia coli
Tanaka et al. Insulin‐like growth factor I receptors and insulin‐like growth factor‐binding proteins in human parathyroid tumors
WO1998042747A1 (fr) Polypeptide exerçant une activite de regulation de l'appetit
JPH0779701B2 (ja) 成長ホルモン放出因子を含むハイブリドポリペプチドをコ−ドする遺伝子
US5973115A (en) Method for potentiating and inhibiting insulin-like growth factor activity